Current status of the CLIO project

CLIO (Cryogenic Laser Interferometer Observatory) is a Japanese gravitational wave detector project. One of the main purposes of CLIO is to demonstrate thermal-noise suppression by cooling mirrors for a future Japanese project, LCGT (Large-scale Cryogenic Gravitational Telescope). The CLIO site is in Kamioka mine, as is LCGT. The progress of CLIO between 2005 and 2007 (room- and cryogenic-temperature experiments) is introduced in this article. In a room-temperature experiment, we made efforts to improve the sensitivity. The current best sensitivity at 300 K is about $6 \times 10^{-21} /\sqrt{\rm Hz}$ around 400 Hz. Below 20 Hz, the strain (not displacement) sensitivity is comparable to that of LIGO, although the baselines of CLIO are 40-times shorter (CLIO: 100m, LIGO: 4km). This is because seismic noise is extremely small in Kamioka mine. We operated the interferometer at room temperature for gravitational wave observations. We obtained 86 hours of data. In the cryogenic experiment, it was confirmed that the mirrors were sufficiently cooled (14 K). However, we found that the radiation shield ducts transferred 300K radiation into the cryostat more effectively than we had expected. We observed that noise caused by pure aluminum wires to suspend a mirror was suppressed by cooling the mirror.Comment: 8 pages, 9 figures. Amaldi7 proceedings, J. Phys.: Conf. Ser. (accepted

Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry

<p>Abstract</p> <p>Background</p> <p>Esophageal squamous cell carcinoma (ESCC) is the sixth most frequent neoplasia in Brazil. It is usually associated with a poor prognosis because it is often at an advanced stage when diagnosed and there is a high frequency of lymph node metastases. It is important to know what prognostic factors can facilitate diagnosis, optimize therapeutic decisions, and improve the survival of these patients. A member of the epidermal growth factor receptor (EGFR) family, c-erbB-2, has received much attention because of its therapeutic implications; however, few studies involving fluorescence <it>in situ </it>hybridization (FISH) analysis of HER-2/neu gene amplification and protein expression in ESCC have been conducted. The aim of this study was to verify the presence of HER-2/neu gene amplification using FISH, and to correlate the results with immunohistochemical expression and clinical-pathological findings.</p> <p>Methods</p> <p>One hundred and ninety-nine ESCC cases were evaluated using the Tissue Microarray (TMA) technique. A polyclonal antibody against c-erbB-2 was used for immunohistochemistry. Analyses were based on the membrane staining pattern. The results were classified according to the Herceptest criteria (DAKO): negative (0/1+), potential positive (2+) and positive (3+). The FISH reactions were performed according to the FISH HER2 PharmDx (DAKO) protocol. In each case, 100 tumor nuclei were evaluated. Cases showing a gene/CEN17 fluorescence ratio ≥ 2 were considered positive for gene amplification.</p> <p>Results</p> <p>The c-erbB-2 expression was negative in 117/185 cases (63.2%) and positive in 68 (36.8%), of which 56 (30.3%) were 2+ and 12 (6.5%) were 3+. No significant associations were found among protein expression, clinicopathological data and overall survival. Among the 47 cases analyzed, 38 (80.9%) showed no gene amplification while 9 (19.1%) showed amplification, as demonstrated by FISH. Cases that were negative (0/1+) and potential positive (2+) for c-erbB-2 expression by immunohistochemistry showed no gene amplification. However, all cases with gene amplification were positive (3+) by immunohistochemistry. According to univariate analysis, there was a significant difference (p = 0.003) in survival rates when cases with and without HER-2/neu amplification were compared.</p> <p>Conclusion</p> <p>Our data demonstrate the correspondence between gene amplification and protein expression of HER-2/neu. Gene amplification is an indicator of poor prognosis in ESCC.</p